In this series, we measure how swiftly a company turns cash into goods or services and back into cash. We'll use a quick, relatively foolproof tool known as the cash conversion cycle, or CCC for short ...

There's no foolproof way to know the future for Syneron Medical (Nasdaq: ELOS) or any other company. However, certain clues may help you see potential stumbles before they happen -- and before your ...

YOKNEAM, Israel, Oct. 3, 2012 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, honored Dr. Shimon Eckhouse, its founder and the inventor of IPL ...

For the quarter ended Sep. 30 (Q3), Syneron Medical missed estimates on revenues and missed estimates on earnings per share. Compared to the prior-year quarter, revenue increased and GAAP loss per ...

IRVINE, Calif. and LONDON, April 3, 2017 /PRNewswire/ — Syneron Medical Ltd. (NASDAQ: ELOS), a leading global non-surgical aesthetic device company, and Apax Partners, a leading global private equity ...

Syneron Medical Ltd. and Candela Corporation to Merge Creating a Leading Global Aesthetic Device Company Combination of Syneron and Candela creates the most comprehensive aesthetic device product ...

Syneron Medical (Nasdaq: ELOS) reported earnings on Feb. 9. Here are the numbers you need to know. The 10-second takeaway For the quarter ended Dec. 31 (Q4), Syneron Medical missed estimates on ...

YOKNEAM, ISRAEL -- (MARKET WIRE) -- 11/10/2008 -- Syneron Medical Ltd. (NASDAQ: ELOS), an innovator in the development, marketing and sales of elos TM combined-energy medical aesthetic devices, today ...

Acquisition of Danish Ellipse adds globally renowned IPL and laser technologies to Syneron Candela's portfolio, further strengthening their position in multi-application, multi-technology devices ...

BEIJING, March 21, 2025 /PRNewswire/ -- Syneron Bio, a cutting-edge oral macrocyclic peptide drug biotech company, announced today a strategic collaboration with the global biopharmaceutical leader ...

BEIJING, Dec. 18, 2025 /PRNewswire/ -- Syneron Bio, an macrocyclic peptide drug discovery company driven by intelligent high-throughput platform, has successfully completed its Series A and A+ ...

Syneron will issue 6.7 mln shares to buy Candela Deal value represents 51 pct premium Deal expected to close by year end Candela shares up 36 pct Syneron stock down 11 pct (Adds analyst comment, ...